z-logo
open-access-imgOpen Access
Alamandine protects against renal ischaemia–reperfusion injury in rats via inhibiting oxidative stress
Author(s) -
Jiabin Zhu,
Junyi Qiu,
Xu Wang,
Hongxia Ma,
Ke Jiang
Publication year - 2021
Publication title -
journal of pharmacy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.745
H-Index - 118
eISSN - 2042-7158
pISSN - 0022-3573
DOI - 10.1093/jpp/rgab091
Subject(s) - oxidative stress , kidney , cystatin c , blood urea nitrogen , renal function , creatinine , endocrinology , renal ischemia , medicine , ischemia , pharmacology , apoptosis , inflammation , reperfusion injury , chemistry , biochemistry
Objective This study was to determine whether alamandine (Ala) could reduce ischaemia and reperfusion (I/R) injury of kidney in rats. Methods Renal I/R was induced by an occlusion of bilateral renal arteries for 70 min and a 24-h reperfusion in vivo, and rat kidney proximal tubular epithelial cells NRK52E were exposed to 24 h of hypoxia and followed by 3-h reoxygenation (H/R) in vitro. Results The elevated serum creatinine (Cr), blood cystatin C (CysC) and blood urea nitrogen (BUN) levels in I/R rats were inhibited by Ala treatment. Tumour necrosis factor alpha (TNF)-α, IL-1β, IL-6, cleaved caspase-3, cleaved caspase-8 and Bax were increased, and Bcl2 was reduced in the kidney of I/R rats, which were reversed by Ala administration. Ala reversed the increase of TNF-α, IL-1β, IL-6, cleaved caspase-3, cleaved caspase-8 and Bax and the decrease of Bcl2 in the H/R NRK52E cells. Ala could also inhibit the increase of oxidative stress levels in the kidney of I/R rats. NADPH oxidase 1 (Nox1) overexpression reversed the improving effects of Ala on renal function, inflammation and apoptosis of I/R rats. Conclusion These results indicated that Ala could improve renal function, attenuate inflammation and apoptosis in the kidney of I/R rats via inhibiting oxidative stress.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here